UBS Group AG Decreases Stock Holdings in Haemonetics Corporation $HAE

UBS Group AG trimmed its stake in shares of Haemonetics Corporation (NYSE:HAE) by 60.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 539,677 shares of the medical instruments supplier’s stock after selling 835,394 shares during the period. UBS Group AG’s holdings in Haemonetics were worth $43,255,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Central Pacific Bank Trust Division raised its holdings in shares of Haemonetics by 2.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock valued at $713,000 after purchasing an additional 188 shares during the last quarter. Quantinno Capital Management LP increased its holdings in Haemonetics by 9.0% during the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 289 shares during the last quarter. True Wealth Design LLC increased its holdings in Haemonetics by 6,700.0% during the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 335 shares during the last quarter. Envestnet Asset Management Inc. raised its position in Haemonetics by 0.8% in the third quarter. Envestnet Asset Management Inc. now owns 40,174 shares of the medical instruments supplier’s stock worth $1,958,000 after acquiring an additional 338 shares during the period. Finally, Empowered Funds LLC boosted its stake in shares of Haemonetics by 9.1% during the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Price Performance

NYSE:HAE opened at $52.52 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The business’s 50-day simple moving average is $59.68 and its two-hundred day simple moving average is $66.65. The stock has a market cap of $2.44 billion, a PE ratio of 14.47, a P/E/G ratio of 1.09 and a beta of 0.53. Haemonetics Corporation has a 52 week low of $47.31 and a 52 week high of $87.32.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, analysts forecast that Haemonetics Corporation will post 4.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HAE has been the subject of a number of recent research reports. Mizuho cut their price objective on shares of Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Citigroup decreased their target price on Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Wednesday, March 11th. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Robert W. Baird set a $81.00 target price on Haemonetics in a report on Friday, February 6th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $82.78.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.